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Abstract: Acute myeloid leukemia (AML), the most common acute leukemia in adults, is a
heterogeneous malignant clonal disorder arising from multipotent hematopoietic progenitor cells
characterized by genetic and concerted epigenetic aberrations. Core binding factor-Leukemia
(CBFL) is characterized by the recurrent reciprocal translocations t(8;21)(q22;q22) or inv(16)(p13;q22)
that, expressing the distinctive RUNX1-RUNX1T1 (also known as Acute myeloid leukemia1-eight
twenty-one, AML1-ETO or RUNX1/ETO) or CBFB-MYH11 (also known as CBFβ-SMMHC)
translocation product respectively, disrupt the essential hematopoietic function of the CBF. In the past
decade, remarkable progress has been achieved in understanding the structure, three-dimensional
(3D) chromosomal topology, and disease-inducing genetic and epigenetic abnormalities of the fusion
proteins that arise from disruption of the CBF subunit alpha and beta genes. Although CBFLs
have a relatively good prognosis compared to other leukemia subtypes, 40–50% of patients still
relapse, requiring intensive chemotherapy and allogenic hematopoietic cell transplantation (alloHCT).
To provide a rationale for the CBFL-associated altered hematopoietic development, in this review, we
summarize the current understanding on the various molecular mechanisms, including dysregulation
of Wnt/β-catenin signaling as an early event that triggers the translocations, playing a pivotal role in
the pathophysiology of CBFL. Translation of these findings into the clinical setting is just beginning
by improvement in risk stratification, MRD assessment, and development of targeted therapies.
Keywords: core binding factor leukemia; AML; RUNX1; RUNX1T1; CBFB; MYH11; miRNA;
chromatin remodeling
1. Introduction
The year 2016 coincided with the 25th anniversary of the first cloning of mammalian Runt (Runt
domain)-related transcription factor 1 (RUNX1) gene, associated with hematologic disorders [1].
RUNX1 (AML1) is a master transcriptional regulator of adult hematopoiesis also involved in the
establishment, maintenance, and functional integrity of hematopoietic stem cells (HSCs) in embryonic
and adult blood compartments [2–4]. AML1 post-translational modifications help create scaffolds
that interact and bind with multiple members recruited to the core binding factor (CBF), promoting
or repressing transcription. At about the same time, the gene encoding CBFB (CBFβ) was identified
as disrupted by the inv(16) in acute myeloid leukemia [5]. Normally, AML1 and CBFβ form
a DNA-binding heterodimer required for binding to the consensus sequence, where it recruits
lineage-specifying transcription factors to regulate hematopoietic differentiation. As the Runt-related
transcription factor (RUNX) gene family plays important roles in tissue-specific gene expression, it is
frequently involved in the malignant transformation of the hematopoietic system. Acute leukemias
characterized by the presence of t(8;21) or inv(16) are defined core-binding factor Leukemias (CBFLs),
since they both alter the CBF transcription factor complex [6]. Approximately 30% and 13–15%
of newly diagnosed pediatric and adult AML patients, respectively, are diagnosed as CBFLs [7].
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Although the CBFLs are categorized into a favorable-risk group as compared with other subtypes of
AML, approximately 30–40% of the patients still relapse and may require allogeneic hematopoietic
cell transplantation (HCT) [8,9]. RUNX1–RUNX1T1 and CBFB–MYH11 translocations may represent
acquired initiating events occurring in hematopoietic progenitors. However, little is known about the
molecular mechanisms that drive the generation of the t(8;21) or inv(16), after which leukemia clonally
evolves through accumulation of secondary mutations. The hypothesis that Wnt signaling promotes
genomic proximity between RUNX1 and RUNX1T1 has been recently examined by experiments
establishing that Wnt/β-catenin signaling supports RUNX1 and RUNX1T1 expression in hematopoietic
precursors and provides spatial information, indicating that transcription of these genes is likely
occurring into RNA-polymerase-II nuclear factories (RNAPII-Ser5) [10]. These results suggest a
Wnt-mediated model in which an upstream molecular mechanism is capable of favoring and guiding
the translocation event [11]. The incremental improvements in understanding the genetic and molecular
basis of CBFLs and their association with distinct clinical and biological features provide insights
into previously unappreciated cooperating pathways [12,13]. At diagnosis, the disease consists of
heterogeneous clusters of cells widely differing from one another in terms of additional genetic
lesions, besides sharing the specific chromosomal translocations. Cytogenetic abnormalities that alter
the function of the CBF are often associated with specific receptor tyrosine kinase (RTK) mutations,
suggesting that additional genetic abnormalities have an essential role in CBFL pathogenesis [14,15].
Despite a common molecular alteration involving a component of the CBF transcription complex,
AMLs expressing RUNX1-RUNX1T1 or CBFB-MYH11 alterations display a remarkably different
genome-wide spectrum of cooperating mutations [14]. Recent studies clearly indicate that AMLs with
t(8;21)(q22;q22) and AMLs with inv(16)(p13q22) show different biological and clinical characteristics,
supporting the notion that they represent two distinct diseases [7,16]. A series of concomitant evidence
in the CBFL proved the existence of a preleukemic phase confirmed by a prolonged latency observed
in experimental models between the occurrence of RUNX1-RUNX1T1 CBF translocation and the
development of overt leukemia [17,18], the persistence of CBFL translocations in normal HSC detected
from patients in remission [19–21], and the maintenance of RUNX1-RUNX1T1 at diagnosis and at
relapses. NRAS (neuroblastoma RAS viral oncogene) is the most frequently mutated gene in CBFL,
and over 60% of the cases harbor activating mutations in NRAS, KIT (v-kit Hardy-Zuckerman 4 feline
sarcoma viral oncogene homolog), FLT3 (FMS-like tyrosine kinase 3), KRAS (Kirsten rat sarcoma
2 viral oncogene homolog), PTPN11 (protein tyrosine phosphatase non receptor type 11), and/or
loss-of-function mutations in NF1 (neurofibromin1) [9,14,15]. Integrated mutational analysis of the
genetic and epigenetic changes that are relevant to the pathogenesis of CBFL would be required for a
better risk stratification of patients who would benefit from dose-intensified induction chemotherapy
or novel targeted therapies. AML1-ETO (eight twenty-one) (RUNX1-RUNX1T1) is the chimeric protein
formed as a consequence of the t(8;21) chromosomal rearrangement, which is among the most recurrent
cytogenetic rearrangements in de novo AML. The molecular mechanisms through which AML1-ETO
fusion protein exerts multiple effects are not fully elucidated, yet all have focused on its strong repressor
function. Moreover, several studies documented the multifunctionality of AML1-ETO fusion protein,
including impaired differentiation, apoptosis inhibition, and signal activation for cell proliferation.
This model might be oversimplified; however, there is convincing evidence supporting the hypothesis
that leukemias are induced by cooperation between alterations in protein-coding genes and microRNAs
(miRNAs), an entire novel epigenetic targets linked to leukemia development [22]. The consequences
of altered expression and epigenetic status of miRNAs in CBF leukemias have been reported by us and
other groups, unveiling that microRNAs are extensively integrated into the molecular networks that
control leukemic development and progression [23–28]. Therefore, in this review, we summarize a
synopsis of recent studies on comprehensive molecular profiles in CBF leukemias, providing a rationale
for translation of the accumulating molecular evidence into clinical trials for better therapies to CBF
leukemia patients.
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2. Core Binding Factor Complex: A Critical Role in Hematopoietic Stem Cell Fate
The CBF is a transcription factor complex, which consists of a distinct DNA-binding CBFα subunit
(RUNX1, 2, or 3), and its non-DNA-binding heterodimerization partner CBFβ subunit (encoded
by the CBFB gene). AML1 is a master regulatory protein expressed throughout all hematopoietic
lineages. The RUNX1 and CBFB genes are required for hematopoietic stem cells’ (HSCs) emergence
and formation during definitive HSC development through to their terminal differentiation, and
are key regulators of hematopoiesis at several steps [29,30]. The loss of definitive hematopoiesis
observed in Runx1−/− or Cbfb−/− knockout mice and an expanded HSC compartment in conditional
Runx1-deficient mice highlight their complex interplay in orchestrating the accurate maintenance
of hematopoietic stem cell differentiation [29–35]. The heterodimerization with CBFβ leads to the
phosphorylation of RUNX1, which in turn induces p300 (encoded by EP300) phosphorylation by
homeodomain interacting kinase 2 (HIPK2) in AML1 [36]. By binding to the core-enhancer sequence,
AML1/CBFβ complex functions as an organizing element recruiting other DNA-binding proteins,
transcription factors, and co-regulators able to activate-or in some cases, repress-the target gene’s
transcription. Heterodimerization with core-binding factor-β (CBFβ) confers enhanced DNA binding
ability, mediated by the Runt domain in AML1. The presence of CBFβ subunit increases the affinity
for DNA and, consistent with predictions, shows a significant enhancement (>40-fold enhancement)
of Runt domain DNA binding of full-length AML1 (Figure 1) [37]. RUNX1 and CBFB are frequent
targets of gene rearrangements through chromosomal translocations and mutations that are associated
with human leukemias. RUNX1 is involved in t(8;21)(q22;q22) and t(12;21)(p13;q22) in acute myeloid
and lymphocytic leukemias, and CBFB is rearranged in acute myeloid leukemias by inv(16)(p13;q22),
t(16;16), and del(16)(q22). These cytogenetic alterations lead to the expression of fusion proteins that
disrupt the heterodimeric CBF complex signaling with a dominant prevalence.
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Figure 1. Schematic representation of the core binding factor transcriptional activation complex. 
DNA binding and heterodimerization with core binding factor-β (CBFβ) are mediated by the Runt 
domain in Acute myeloid leukemia1 (AML1 or RUNX1). The interaction with CBFβ leads to the 
phosphorylation of AML1, which in turn induces p300 phosphorylation, and this is mediated by 
homeodomain interacting kinase 2 (HIPK2) in AML1. CBP/p300 (CREB binding protein CBP and 
EP300); C/EBPα (CCAAT/enhancer binding protein alpha); P/CAF (P300/CBP-associated factor); 
AML1 (acute myeloid leukemia 1 protein); CBFβ (core binding factor subunit beta); LEF1 (lymphoid 
enhancer-binding factor 1); ALY (Aly/REF export factor); ETS-1 (v-ets erythroblastosis virus E26 
oncogene homolog 11). 
  
Figure 1. Schematic representation of the core binding factor transcriptional activation complex.
DNA binding and heterodimerization with core binding factor-β (CBFβ) are mediated by the Runt
domain in Acute myeloid leukemia1 (AML1 or RUNX1). The interaction with CBFβ leads to the
phosphorylation of AML1, which in turn induces p300 phosphorylation, and this is mediated by
homeodomain interacting kinase 2 (HIPK2) in AML1. CBP/p300 (CREB binding protei CBP and EP300);
C/EBPα (CCAAT/enhancer binding protein alpha); P/CAF (P300/CBP-associated factor); AML1 (acute
myeloid leukemia 1 protein); CBFβ (core binding factor subunit beta); LEF1 (lymphoid enhancer-binding
factor 1); ALY (Aly/REF export factor); ETS-1 (v-ets erythroblastosis virus E26 oncogene homolog 11).
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3. Leukemia Triggered by RUNX1–RUNX1T1
AML1-ETO in frame fusion protein joins the N-terminal 177 amino acids of AML1 (encoded
by RUNX1) to nearly all of ETO (encoded by RUNX1T1), and functions as a dominant repressor for
the majority of RUNX1-responsive hematopoietic genes and microRNA (miRNA) non-coding genes.
Consequently, in RUNX1-RUNX1T1, the DNA-binding Runt domain of RUNX1 is joined to RUNX1T1,
creating a fusion transcript lacking the RUNX1 transcription activation domain. The structural
insights show four essential interactions for AML1-ETO activity: DNA and CBFβ binding by the Runt
domain, oligomerization through the HHR domain, and E-protein binding by the HHR domain [38–42].
The presence of chromosomal rearrangements, such as t(8;21) or inv(16), is associated with a unique
DNA methylation patterning that predicts distinct patient outcomes, suggesting for the CBF fusion
proteins also a role as epigenotype modifier [43]. The underlying mechanisms involve the AML1-ETO
capacity to recruit DNA methyltransferases (DNMTs) to target tumor-suppressor genes by concerted
action with certain transcriptional repressors (Figure 2) [44–47]. AML1-ETO cooperates with HIF1α
to transactivate DNMT3a gene and shapes a positive regulatory circuit that contributes to DNA
methylation signature, specifically for the non-AML1–ETO targets, leading to a DNA hypermethylation
profile in AML [48]. Moreover, Ptasinska and colleagues observed that depletion of AML1-ETO
and subsequent cell differentiation involves not only loss of repression, but is also associated with
a redistribution of RUNX1-binding activity throughout the genome that restores, on a global scale,
the epigenetic alterations mediated by the fusion protein [49]. This effect, therefore, is obtained
not only through loss of repression, but involves an increased recruitment of transcription factors
to additional sites, depending on AML1 interactions with other transcriptional activators, such as
C/EBPα and PU.1, whose activity is altered by AML1-ETO [50,51]. ETO is a member of E-box family
of transcription factors, and contains four nervy homology regions (NHR 1–4) that interact with
several nuclear repressors (N-CoR, SMRT, mSin3A), including the histone deacetylases (HDACs 1–3),
primarily through the NHR2 and NHR4 domains [44,52,53]. AML1-ETO also interacts with the DNA
methyltransferase DNMT1 to promote DNA methylation and mediates transcriptional repression
(Figure 2) [45]. However, increasing evidences from mammalian cell systems and mouse genetic
models suggest that the relationship between AML1-ETO and native AML1 may be more complex,
indicating that AML1-ETO depends on some functions of native AML1 to exert its proleukemogenic
properties [6,54,55]. Genome-wide ChIP-Seq and RNA-Seq data recently revealed that AML1 is a
member of the transcription factor complex containing AML1-ETO, and that relative binding signals
on chromatin determine which genes are repressed or activated by AML1/AML1-ETO complex [56].
Thus, these new important findings indicate that the malignant cell phenotype of t(8;21) leukemia is
sustained by a delicate balance between AML1-ETO and native AML1. Translocation-prone genes
are preferentially recruited into transcription factories with active RNA polymerase II (RNAPII-Ser5)
and need to be positioned in close spatial proximity relative to each other prior to translocation.
Mechanisms that drive the generation of the RUNX1-RUNX1T1 translocation have been poorly
understood, but a recent report established that the Wnt/β-catenin signaling enhances transcription
and genomic proximity of RUNX1 and RUNX1T1 genes, which seems to promote the generation of the
RUNX1-RUNX1T1 fusion gene [11]. These observations describe the enhanced RUNX1T1 and RUNX1
expression in hematopoietic precursors by Wnt/β-catenin signaling and suggest a nuclear topography
of transcription likely occurring into specialized nuclear factories, thereby increasing the potential for
a chromosomal translocation event (Figure 3).
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Figure 2. Schematic representation of the AML1–ETO (eight twenty one) repressor complex assembly.
Transcriptional repression complex AML1/AML1-ETO recruits corepressors, including NCOR (nuclear
receptor corepressor 1), HDACs (histone deacetylases), mSin3A (SIN3 transcription regulator family
member A), and also interacts with DNMT1 (DNA methyltransferase 1) to promote DNA methylation
and to repress target genes and miRNAs expression.
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4. Leukemia Triggered by CBFβ-MYH11
The CBFβ-SMMHC (smooth muscle myosin heavy chain, encoded by MYH11) fusion protein
exhibits a higher binding affinity for AML1 than wild-type CBFβ. In addition to the RUNX-binding
domain in CBFβ, it contains an additional RUNX-binding domain in the SMMHC portion of the
fusion protein. The CBFβ-SMMHC interacts specifically with transcriptional inhibitors and HDACs,
such as mSin3A and HDAC8, through an unexpected domain within the SMMHC region, thereby
repressing AML1-mediated gene regulation. [57]. Therefore, CBFβ–SMMHC fusion protein acts
as a transcriptional repressor, and might do so by sequestering AML1 on actin filaments in the
cytoplasm. However, the majority of CBFβ–SMMHC target genes are actively transcribed, including
genes such as ID1 (inhibitor of DNA binding 1), LMO1 (LIM domain only 1, rhombotin 1), and
JAG1 (Jagged 1) involved in hematopoietic stem cell self-renewal, and repressed upon fusion protein
knockdown (Figure 4). An intrinsic inability of CBFβ-SMMHC to provide CBFβ function in vivo has
Cancers 2019, 11, 1973 6 of 21
also emerged, based on its failure to complete hematopoietic recovery by Cbfb–/– mouse embryonic
stem (ES) cells impaired in their capacity to generate definitive erythroid and myeloid elements [58].
Otherwise, the CBFβ–SMMHC fusion protein is predominantly recruited to promoters engaged by
AML1, where it interacts with TAL1 (T-cell acute leukemia 1), FLI1 (Friend leukemia virus integration
1), and TBP-associated factors (TAFs), in synergy with a variety of hematopoietic transcription
factors (ERG, GATA2, and PU.1/SPI1), as well as epigenetic coregulators, including EP300 (E1A
binding protein p300) and HDAC1 (histone deacetylase 1). Recent results suggest that HDAC1 is
an important component of the AML1/CBFβ-SMMHC fusion complex, which functions to activate
transcription of specific target genes. The authors found that in vivo treatment with the HDAC1
inhibitor induced differentiation and apoptosis of leukemia cells, indicating HDAC1 as a potential
therapeutic target [59]. These findings suggest an important role for CBFβ-SMMHC in regulating
the expression of genes essential for emergence of the hematopoietic stem cell [60]. Therefore, AML1
activity is required for CBFB-MYH11-induced leukemogenesis [61], also through the activity of the
chromodomain helicase DNA-binding protein-7 (CHD7), which is an ATP-dependent chromatin
remodeling factor interacting with AML1/CBFβ–SMMHC complex and altering the expression of its
target genes. Chd7 deficiency in Chd7f/fMx1-CreCbfb+ /56M mice, which expresses the Cbfb-MYH11 fusion
gene, delayed Cbfb–MYH11-induced leukemia in both primary and transplanted mice [62]. Normally,
the interacting interface between AML1 and CBFβ, which allows the heterodimerization [63], is retained
in CBFβ-SMMHC. Moreover, the fusion between the amino-terminal heterodimerization domain of
CBFβ and the C-terminal coiled-coil region of SMMHC creates a novel binding site for AML1, called the
AML1 (RUNX1) high-affinity binding domain (HABD) [64]. Therefore, the CBFβ-SMMHC binds AML1
at two sites, resulting in a higher binding affinity for AML1 than wild-type CBFβ [65]. In patients with
one allele of the wild-type CBFB and one allele of CBFB-MYH11, AML1 will be preferentially bound to
the fusion protein [64,65]. This high-affinity AML1 binding has been proposed to explain the dominant
negative role of CBFβ-SMMHC by sequestering AML1 from its targets [64]. However, knock-in mice
expressing Cbfb-MYH11 with a HABD deletion unexpectedly potentiated its leukemogenic activity,
developed leukemia faster, even though hematopoietic defects associated with Runx1-inhibition
were partially rescued, suggesting that AML1-dominant inhibition may not be a critical step for
leukemogenesis by CBFβ-SMMHC [55]. CBFβ-SMMHC was also shown to bind and sequester HIPK2,
preventing the critical AML1/p300 phosphorylation to mislocalized CBFβ-SMMHC complexes [66].
Martens and colleagues [67] analyzed inv(16) AMLs by multiple transcriptomic and epigenomic profiles
with the aim to investigate whether CBFB–MYH11 specifically blocks megakaryocyte/erythrocyte
differentiation in the context of human hematopoiesis. Findings revealed that CBFβ-SMMHC seems to
be involved in transcription deregulation and occupancy replacement of the transcription factors GATA2
(GATA binding protein 2) and KLF1 (Kruppel-like factor 1), interfering with normal differentiation.
These results indicate that the attenuating expression of GATA2/KLF1, induced by CBFβ–SMMHC
fusion, inhibits primed megakaryopoiesis [67]. On the other hand, a recent paper [68] showed that Gata2
determines its distinct effects in association with Cbfb-MYH11 in two different stages. Up-regulated
Gata2 gene is important in preleukemic Cbfb-MYH11 knock-in mice. Heterozygous knockout of Gata2
in Cbfb-MYH11 mice delayed leukemia onset. However, despite slower development of leukemia,
the Cbfb-MYH11 Gata2-deficient mice showed a more aggressive phenotype at the leukemic stage.
These findings may reflect the clinical observation of GATA2 recurrent deletions in relapsed CBFL
patients [69]. Therefore, GATA2 up-regulation contributes to CBFB-MYH11 leukemogenesis in the
early stage, and deficiency could be involved in the relapse/aggressive evolution of CBFL.
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additional RUNX-binding domain in the SMMHC. Fusion protein has the ability to interact specifically
with mSin3A and HDAC8 (histone deacetylase 8) through an unexpected repression domain within the
SMMHC portion. GATA2 (GATA binding protein 2); KLF1 (Kruppel-like factor 1); ID1 (inhibitor of
DNA binding 1); LMO1 (LIM domain only 1); JAG1 (jagged canonical notch ligand 1).
5. MicroRNA Circuitries Contribute to CBF-Mediated Leukemogenesis
In addition to genetic alterations in the chromatin state that affect gene expression and enrichment
for mutations in genes encoding proteins essential for mRNA splicing [70], alterations in the expression
of long non-coding RNA (lncRNA) [71], as well as microRNAs (miRNAs), are widely suspected to play
a critical role in leukemia initiation and outcome prediction. MicroRNAs are a class of small non-coding
RNAs elements (≈20–22 nt) implicated in differentiation of mammalian blood cell lineages through
the post-transcriptional modulation of gene expression by binding to the 3′ untranslated region of
mRNAs and down-regulation of their translation to protein [72]. The role of lineage-specific miRNAs in
hematopoiesis was largely determined from profiling studies that revealed distinct miRNA expression
patterns at various stages of hematopoietic development [73–76]. The expression levels of several
miRNA genes show abundant natural variation in nearly all physiological processes involving the
formation and maintenance of the human blood hierarchy [77,78]. Human granulocytic differentiation
is controlled by miR-223, a key member of an integrated regulatory circuit, including C/EBPα and
NFI-A [23], and miR-221/miR-222 cluster were found to target the oncogene KIT [73]. The causal
mechanisms and molecular player responsible for the widespread dysregulation of miRNA expression
in AMLs, which can function as either oncomiRs or tumor suppressors, are only limitedly known.
Specific chromosomal and genetic abnormalities in each AML subtype are likely to contribute to the
global non-coding transcriptome. The genomic abnormalities, previously described for protein-coding
genes such as chromosomal rearrangements, are found to influence the activity of miRNAs through a
variety of mechanisms [27], playing a role in nearly all aspects of AML development [79]. The biological
phenomenon where several RNA species regulate one another by competing for binding to a limited
pool of shared miRNAs has been proposed as competing endogenous RNAs (ceRNAs) [80]. The
potential of the aberrantly overexpressed RUNX1T1 3′UTR, acting as ceRNAs and contributing to
t(8;21) alterations of transcriptional balance during AML development, has been addressed by a recent
report [81]. Results showed a total of 605 RUNX1T1 ceRNAs significantly enriched in gene ontology
(GO) categories mainly associated with leukemia, suggesting the hypothesis that RUNX1T1 may also
act as a miRNA sponge in t(8;21) AML, and contributing to explain the complex pattern of gene
expression alterations observed in CBFL.
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5.1. Down-Regulation of mir-222/221 in AML with Deranged Core Binding Factor
One of the most common mechanisms through which miRNA expression dysregulates in AML is
yielded by altered transcription factors or oncogenic fusion proteins through epigenetic alterations.
Remarkably, the expression of AML1-ETO triggers heterochromatic silencing of genomic regions
generating the miR-223 by recruiting chromatin remodeling enzymes at a RUNX1-binding site on the
pre-miR-223 gene [82]. The AML1-ETO-associated complex resets the miR-223 gene to a repressed state
by changes in chromatin conformation, contributing to the granulocytic differentiation block of the
myeloid precursors. Of interest that either ectopic miR-223 expression, down-regulation of AML1-ETO
protein levels, or the use of demethylating agents reactivates miR-223 expression and restore myeloid
differentiation in t(8;21)-AML blasts [82]. Furthermore, the expression level of both KIT mRNA and
proteins is much higher in the CBFL, with either wild-type or mutant KIT, than in leukemia cells negative
for CBF rearrangements [83,84]. Gain-of-function KIT mutations, resulting in constitutive tyrosine
kinase activity, are significantly enriched in patients with core binding factor leukemia [85,86], and
these mutations are associated in t(8;21)-related leukemia with unfavorable outcome [87,88]. Aberrant
activation of KIT results in MYC (MYC Proto-Oncogene, BHLH Transcription Factor)-dependent
miR-29b down-regulation and an increase in Sp1 expression that results in KIT overexpression by NFkB
transactivation, implicating deregulation of the protein–miRNA network Sp1/NFkB/HDAC/miR-29b
in KIT-driven leukemia [89]. However, the molecular mechanisms explaining the peculiar association
between rearrangements involving the CBF subunits and overexpression of either wild-type or
mutant KIT receptor appear much more complex. We reported that CBFL blasts with either t(8;21)
or inv(16) rearrangements, characterized by higher expression levels of KIT, display a significantly
lower expression levels of miR-222/221 cluster, a negative modulator of KIT, than non-CBFL blasts.
Consistently, the t(8;21)-derived fusion protein induces transcriptional repression of the pre-miR-222/221
promoter by binding at the evolutionarily conserved RUNX1-binding sites and thus leading to KIT
overexpression [84].
5.2. Epigenetic Silencing of mir-193a Contributes to t(8;21)-Mediated AML
Interestingly, miR-193a represses the expression of multiple target genes, such as RUNX1-RUNX1T1,
DNMT3A (DNA methyltransferase 3 alpha), HDAC3 (histone deacetylase3), KIT, CCND1 (B-cell
leukemia/lymphoma 1, BCL1), and MDM2 (transformed mouse 3T3 cell double minute 2) directly,
and increases PTEN (phosphatase and tensin homolog deleted on chromosome ten) indirectly.
AML1-ETO triggers the heterochromatic silencing at the RUNX1-binding sites of miR-193a by recruiting
chromatin remodeling enzymes and expanding the oncogenic activity of the fusion protein [90].
These further studies add new insights into understanding the concomitant occurrence of CBF
genetic rearrangements and overexpression of wild-type or mutant KIT in CBFL, explaining how
CBF fusion proteins may therefore maintain expression of several genes (i.e., KIT, WT1) by repressing
the expression patterns of their specific miRNAs (Figure 5) [49,84,90]. Another interesting notion
is that KIT-ITD mutant cooperates with canonical Wnt signaling pathway, inactivating GSK3β by
hyperphosphorylation, which results in increased β-catenin stability [91]. Hence, activation of Wnt
signaling plays an important role in KIT-mediated transformation of myeloid cells. Of note, a step
forward suggests that activated Wnt/β-catenin signaling induces RUNX1 transcription mainly through
directβ-catenin binding to TBE Site-II, which is located in a highly conserved region within the P1-distal
promoter of RUNX1 [92]. Therefore, Wnt/β-catenin signaling rapidly enhances RUNX1 expression in
leukemia-derived cell lines and human CD34+ hematopoietic cells, suggesting that transcriptional
deregulation of translocation-prone genes occurs prior to translocation [93]. Furthermore, recent results
highlight the role of Wnt signaling in AML, describing a new rearrangement leading to WNT10B
overexpression, with the exception of clinical contexts with recurrent cytogenetic abnormalities [94],
suggesting a different mechanism promoting Wnt signaling activation in CBFL. In line with these
findings, it appears interesting the functional relevance of Wnt signaling induced by CBFL fusion
proteins via plakoglobin (γ-catenin) induction [95], which provides a possible explanation of the
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different molecular circuitry involved in Wnt signaling activation as a common feature of several
balanced translocations in AML (Figure 5).
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Figure 5. Schematic representation of the A L1-ETO integrated regulatory network comprised
micro-RNA minicircuitries promoting nt signaling in t(8;21)-AML. AML1-ETO triggers
heterochromatic silencing of genomic regions generating the miR-223, miR-222/221 cluster, miR-193a,
and miR-9-1 by recruiting chromatin remodeling enzymes at their specific RUNX1-binding sites; in turn,
these miRNA repressions generate differentiation impairments and KIT up-modulation that converges
with AML1-ETO to activate the Wnt signaling.
5.3. Epigenetic Mini-Circuit AML1-ETO/miR-9-1/miR-383 Contributes to t(8;21) Leukemogenesis
Additionally, new information indicates a feedback minicircuitry through which the expression
of miR-9-1 was decreased by AML1-ETO repression activity, leading to increasing level of
RUNX1, RUNX1T1, and RUNX1–RUNX1T1, which are all targeted by miR-9-1 (Figure 5) [26].
As thanatos-associated protein 10 (THAP10) is a nuclear protein that inhibits myeloid proliferation
and promotes differentiation both in vitro and in vivo, AML1-ETO inhibits expression of the tumor
suppressor THAP10 directly via epigenetic suppression of the THAP10 promoter and indirectly through
transcriptional activation of miR-383 in t(8;21) AML, unveiling a novel epigenetic mini-circuitry
of AML1-ETO/THAP10/miR-383 [28]. Many complexities of miRNA biology have already shed
additional light on our understanding of how miRNAs function in AML, substantially improving our
understanding of how miRNAs synergize within CBFL cells.
6. The Genomic Landscape of Core-Binding Factor Acute Myeloid Leukemias
Current treatment guidelines for CBFL with t(8;21) do not take into account heterogeneity in
these patients, and thus, all CBFL patients generally receive the same inductio and consolidation
tr atments. M y comprehensive genetic analyses ognize th t combination of several genetic
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alterations is associated with the development of CBFL, and is necessary for a better risk stratification
in this leukemia. Although the spectrum of mutations for both CBFL subtypes is similar to the reported
signature for AML [96], gene expression and mutation profiling of CBFL identified t(8;21) and inv(16)
patients as two distinct subgroups [97], reflecting alternative signals activated in each subtype of
CBFL [98]. Moreover, 35% of CBFL patients have two or more mutations in tyrosine kinase (TK)
genes coding for pathway effectors (especially KIT, FLT3, and RAS genes); these findings highlight
the multiclonality of CBFL. NRAS is the most frequently mutated gene in CBFL, more common
in CBFB–MYH11 with a different spectrum of mutations, yet its mutations are not associated with
outcome. KIT mutations are found in ~40% of CBFL with t(8;21) and ~33% with inv(16); additionally,
an enrichment of exon 17 KIT mutations has been documented in RUNX1–RUNX1T1 patients, and are
associated with worse outcome [87,99–101]. Recent large study created an “International CBF group
index for t(8;21)” and validated a new risk scoring system, showing that older age, higher WBC index at
diagnosis [102], and KIT D816V/Y mutations were risk factors associated with treatment failure (relapse
or death) [103]. These studies strongly support the adverse effect of a KIT mutation in the context
of CBFL. In addition, a novel finding indicates that pseudodiploidy was also a risk factor in t(8;21).
High-risk score patients may benefit from more intensive approaches in the first complete remission
(CR1) [103]. Mutations affecting FLT3–ITD are present in only 3% of inv(16) AML, whereas they occur in
10% of t(8;21) leukemia patients. In addition to mutations in genes involving TK signaling, alterations
in MGA (MAX dimerization protein), a negative regulator of MYC signaling, were also recurrently
identified in CBFL [104]. Recent results identified CCND2 (cyclin D2) expression as key transmitter
of RUNX–RUNX1T1-driven AML, promoting cell cycle progression with the cooperation of the
transcription factor Activator protein 1 (AP-1), and suggesting new potentially targetable complexes
in CBFL [14,105]. Loss-of-function mutations in genes that regulate chromatin-modifying genes
(ASXL1/2, EZH2, KDM6A, BCOR/BCORL1, EED, SETD2, KMT2D, KMT2C, and CREBBP) or in genes
implicated in the cohesin complex (RAD21, SMC1A, SMC3, STAG2) were observed almost exclusively
in RUNX1–RUNX1T1 AML. Cohesin mutations led to a state of increased chromatin accessibility
of binding sites for master hematopoietic transcription factors such as AML1 [106]. These findings
suggest links between cohesin-mediated alterations in chromatin structure, or chromatin modifiers
mutations, and cooperativity with the AML1–ETO fusion oncoprotein, even if cohesin mutations
concerned less than 10% of CBFL [15]. CBFL patients with mutations in the above members of the
complex, responsible for sister chromatid cohesion during mitosis and DNA repair, lack evidence
of aneuploidy or an increase rate of genetic instability without any effect on the outcome. Recently,
mutations in ASXL1 (additional sex combs like 1), ASXL2 (additional sex combs like 2), ZBTB7A
(zinc finger and BTB domain conteining 7A), CCND2, and DHX15 (DEAH-box helicase 15) have been
frequently identified in RUNX1–RUNX1T1 but not in CBFB–MYH11 AML patients [14,107]. ASXL1
or ASXL2 truncating mutations, which inhibit myeloid differentiation and induce a myelodysplastic
syndrome-like disease in mice [108,109], have been described in ~35% of t(8;21) while are absent in
inv(16) AML [15,110,111]. Of interest, chromatin modifier ASXL1, as well as cohesin gene mutations,
are co-occurring alterations significantly enriched in patients with mutated RUNX1 AML [112,113].
The nature of cooperating mutations associated with t(8;21)-mediated leukemogenesis is evidenced
by additional cytogenetic abnormalities such as trisomy 8 and 4, chromosome 9 deletion, and loss of
one of the sex chromosomes [114–116]. Increased dosage of the mutated KIT (mapped at 4q12) can
occur due to trisomy 4, leading to duplication of the mutant KIT allele, and suggesting an additional
contribution to leukemogenesis [86]. These observations are supported by a higher dosage of N822K
KIT mutated allele linked to an increased segregation of minichromosomes derived from chromosome
4 that preserve the pericentromeric region containing the KIT gene in the t(8;21) positive Kasumi-1 cell
line [117]. The most common additional cytogenetic features associated with t(8;21) include loss of
either the X or Y chromosome in a disproportionally large number of cases (50–60%), and del(9)(q22)
in 15–25% of patients. It has been proposed that haploinsufficiency must be occurring at genes located
within shared sequences in the pseudoautosomal regions (PARs) on the X and Y chromosome. A critical
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event potentially explaining the high incidence of loss of sex chromosomes in t(8;21) may be the loss
of CSF2RA (colony stimulating factor 2 receptor alpha subunit) gene, encoding for the α subunit of
the heterodimeric receptor CSF2 (colony-stimulating factor 2), which control granulopoiesis [118].
However, given that the whole sex chromosome is typically missing and not only the individual
CSF2RA locus, it is likely that additional haploinsufficient factors on the sex chromosome are acting to
enhance RUNX1–RUNX1T1-associated leukemogenesis [119]. Sex chromosome loss was reported as a
favorable marker for two-year event-free survival (66.9% vs. 43.0%), and in another study showed
a modestly favorable, but not significant, effect on disease-free survival (DFS) [103]. Moreover, this
last study found that patients with pseudodiploid karyotypes had worse outcome compared with
those with hypodiploidy or hyperdiploidy [103]. In contrast, loss of the Y chromosome showed shorter
disease-free survival (DFS) for male patients [120].
7. Mouse Models for Core Binding Factor Leukemia
The homozygous disruption of Runx1 or Cbfb in murine knockout models exhibits a similar
range of abnormalities associated with developmental defects. These common phenotypes include
severe hematopoietic defects such as lack of HSCs and progenitors leading to midgestation embryonic
lethality between embryonic days (E) 12.5–13.5. Thus, creating mice deficient in Runx1/Cbfb, lacking
the ability to contribute to definitive hematopoiesis, several research groups have shown that the
AML1/CBFβ transcription factor complex is essential in the hematopoietic fate process from the
hemogenic endothelial cells. [29,121–123]. Moreover, all heterozygous Runx1-Runx1t1 knock-in mice
die around 12.5 days of embryogenesis and fail to establish definitive hematopoiesis [124,125]. This
similarity in phenotypes suggests that AML1-ETO effectively neutralizes the normal biologic activity
of the AML1/CBFβ transcriptional factor complex and dominantly blocks AML1 activity during early
development. Both mouse and in-vitro models have shown that the expression of Runx1-Runx1t1 or
Cbfb-Myh11 contribute to leukemogenesis but require additional “hits”. An interesting observation
that emerged from Cre recombinase-mediated conditional AML1-ETO expression transgenic mice is
that the non-leukemic AML1–ETO expressing cells were cytokine-dependent, strongly suggesting that
one signaling pathway that may collaborate with AML1–ETO is cytokine-mediated proliferation or
survival [13,126]. The first step towards CBFL would consist of the acquisition of genetic alterations, like
the CBFL translocations, in modulators of differentiation (class 2 mutations) by the preleukemic clone;
the second step would be the acquisition of activating mutations in cell cycle and proliferation controllers
(class 1 mutations) such as KIT, FLT3, or N-RAS tyrosine kinases [14,86,127–131], and their cooperation
with Runx1-Runx1t1 or Cbfb-Myh11 is thought to be crucial for leukemogenesis [132]. CBFβ-SMMHC
dominantly represses AML1 function, generates defects in definitive hematopoiesis [133], and
predisposes mice to leukemia with cooperating gene mutations [12,134]. Therefore, the fusion
protein alone is necessary but not sufficient to cause leukemia, and activating mutations in genes
encoding for receptor tyrosine kinases (RTKs) or small GTPase represent the most common genetic
events cooperating with CBFL-associated gene fusions [12,126,134]. Although RUNX1-RUNX1T1
and CBFB-MYH11 share a common molecular alteration involving the CBF transcription complex,
they up-regulate specific signaling pathways essential for stem cell self-renewal and have remarkably
different spectra of cooperating mutations [14,95,96,135,136].
The HSCs from adult chimeric mice generated with CbfbCbfb–MYH11/+ ES cells were found to give
rise efficiently to mature erythrocytes, but were unable to differentiate along myeloid and lymphoid
lineages [58], suggesting that the differentiation impairment involves the lympho-myeloid primed
progenitor (LMPP) as from the revised hematopoietic tree [137]. Knockdown of Runx1 inhibits the
growth and survival of Runx1-Runx1t1 leukemia cells [138,139]. Moreover, a variant of the AML1-ETO
fusion protein, Runx1-Runx1t19a (ETO9a), which includes an extra exon 9a of the Runx1t1 gene
that contains C-terminal truncation, was found to be a much more potent inducer of leukemia than
the full-length Runx1-Runx1t1 in mouse retroviral transduction–transplantation model [140]. It has
been hypothesized that the deleted region inhibits the leukemogenic potential of AML1-ETO [141].
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Interestingly Runx1-Runx1t1tr, a C-terminally truncated protein similar to Runx1-Runx1t19a, lost
the ability to inhibit cell cycle progression of myeloid cells, which may contribute to its enhanced
leukemogenic potential [142]. Moreover, the ability to regulate the expression of the CD44 gene of
both RUNX1-RUNX1T1 and its splice variant RUNX-RUNX1T19a links the t(8;21) translocation to the
regulation of a cell adhesion molecule involved in the growth and maintenance of the AML blast/stem
cells [141]. Novel integrative data analyses, together with siRNA-mediated depletion of AML1-ETO,
strongly support the notion that AML1-ETO binds genes associated with the cell structure and cell-cycle
progression affecting transcriptional programs associated with myeloid differentiation, proliferation,
and self-renewal, in addition to those promoting DNA synthesis [49]. H3K9Ac at AML1-ETO-binding
sites show a significant increase after knockdown, which would be compatible with a repressive role of
the fusion protein at these sites.
Critical genes such as CSF2RA (GM-CSF receptor alpha) and IL3RA (IL3 receptor alpha) on human
sex chromosomes are localized to syntenic regions on murine 19 chromosome. The receptors for
granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 all share a
common β chain (βC) but have a ligand-specific α chain [143]. Matsuura and colleagues [118],
in order to explain the selective advantage for sex chromosome loss in t(8;21)-AML, used a
transduction/transplantation assay where Runx1-Runx1t1 was expressed from a retroviral vector
in βc-knockout bone marrow cells, which were then transplanted into irradiated wild-type recipient
animals. Interestingly, loss of βC in association with AML1-ETO significantly accelerated progression
to AML. GM-CSF signaling deficiency is favorable for leukemia development driven by Runx1-Runx1t1
in mouse models. Moreover, GM-CSF signaling inhibits RUNX1-RUNX1T1-mediated leukemogenesis
by reducing the self-renewal potential of hematopoietic stem and progenitor cells in murine bone
marrow and in human t(8;21) Kasumi-1 cells. These findings suggest an unexpected tumor-suppressor
role of GM-CSF in t(8;21) leukemias.
8. Molecular Targeted Therapy of CBFL: The Progress and Future Prospect
Individual genomic characterization may be useful to suggest or not targeted interventions, such
as the use of RTK inhibitors, for instance dasatinib [144,145] or midostaurin [146], in patients carrying
activating KIT and/or FLT3 gene mutations. KIT mutations are common in CBFL and have been
associated with worse prognosis (shorter disease-free survival, relapse-free survival, event-free survival,
overall survival) [147]. A phase III study of gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst
Laboratories) showed that GO abrogated the negative prognostic effect of exon 17 (E17) mutations in
treated patients [148]. Moreover, the outcome of patients harboring KIT mutations in the Cancer and
Leukemia Group B (CALGB) study, appeared not to be worse than that of patients with KIT wild-type
after treatment with dasatinib, implying that a potentially adverse impact of KIT mutations might be
abrogated in treated patients [144]. Conversely, within the German-Austrian AML Study Group trial
(AMLSG 11- 08 trial), no favorable impact after dasatinib administration was noted for patients with
concurrent KIT mutation [145]. Although validation by other studies is needed, the rationale to combine
dasatinib with other compounds was supported by data from a mouse model of t(8;21)-positive and
KIT-mutated leukemia, where the combination of dasatinib with cytarabine prolonged the survival
of the animals compared to the exposure with these drugs as single agents [146,149]. As acquisition
of spliceosome gene mutations result to be the initiating events in clonal hematopoiesis, the use
of spliceosomal modulation to induce synthetic lethality in splicing factor mutant hematological
malignancies, currently being tested in an early phase clinical trial, is quite exciting [150]. CBFL is a
still heterogeneous disease entity, and for better characterization of CBFL risk heterogeneity in the
spirit of precision medicine, it is necessary to elucidate the combinations of genomic abnormalities and
clonal evolutions using refined high-resolution genomic analysis to develop new treatment strategies
for CBFL.
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9. Conclusions
Genetic definition of CBFL patients using deep sequencing approaches illustrate that we are only
beginning to understand how fusion proteins involving the CBF are integrated into the molecular
networks of transcriptional and epigenetic regulators. Despite the generation of in vivo models
helped us to understand how CBFL originates and propagates, we can imagine a future where the
understanding of how expression and CBF fusion proteins activity are modulated during myeloid
leukemia transformation and progression will trigger a true progress to translate into the clinic. Such
achievements will become extremely useful, in a view of individual treatment on the basis of defined
targets. Future studies will be required to identify which CBFL patients could benefit from therapy by
each molecular drug combination targeting a specific pathway.
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